GNCA News and Press, Genocea Biosciences Inc. From 09/22/20

CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s...

Genocea Biosciences (NASDAQ: GNCA )   +11%   announces follow up data from the first five patients vaccinated in Part B of the ongoing GEN-009 Phase 1/2a trial at the European Society for Medical Oncology Virtual Congress 2020. More news on: Genocea Biosciences, Inc., Healthcar...

Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy 100% of patients have immune responses to ATLAS-identified neoantigens CAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Genocea Bios...

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that the company will present incremental follow-up data, including additional tumor scan res...

Genocea Biosciences (NASDAQ: GNCA ) is 1.8% lower postmarket after a registration to offer 21.39M shares by its holders . More news on: Genocea Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...

AstraZeneca reports positive data for nirsevimab AstraZeneca (AZN) announced positive data for nirsevimab for the passive immunization against respiratory syncytial virus ((RSV)) infections in healthy preterm infants. The data showed that the treatment was able to provide favorable resul...

Gainers:  Taoping (NASDAQ: TAOP ) +492% . More news on: Taoping Inc., Edesa Biotech, Inc., DIRTT Environmental Solutions Ltd., Stocks on the move, , Read more ...

Genocea Biosciences (NASDAQ: GNCA ) slumps  20%  premarket on increased volume in apparent response to preliminary data from a Phase 1/2a clinical trial evaluating neoantigen vaccine GEN-009, combined with a checkpoint inhibitor (CPI) (either Merck's Keytruda or Bristol Myers...

Spectrum Pharmaceuticals (NASDAQ: SPPI )   -18%  after pricing equity offering. More news on: Spectrum Pharmaceuticals, Inc., Global Eagle Entertainment Inc., JAKKS Pacific, Inc., Stocks on the move, , Read more ...

Webcast/conference call scheduled today, July 30th at 8:00 a.m. EDT Three of five patients achieved separate RECIST responses after GEN-009 administration GEN-009 elicited antigen-specific CD4 + and CD8 + T cell responses in 100% of treated patients CAMBRIDGE, Mass., July 30, ...